The Market Reports
Call: +1-631-407-1315 / +91-750-729-1479
Email: sales@themarketreports.com
Global Bevacizumab Market Research Report 2025
Synopsis
Bevacizumab, sold under the trade name Avastin, is a medication used to treat a number of types of cancers and a specific eye disease.
The global Bevacizumab market was valued at US$ 61 million in 2023 and is anticipated to reach US$ 82 million by 2030, witnessing a CAGR of 4.4% during the forecast period 2024-2030.
Bevacizumab is a monoclonal antibody used for the treatment of various types of cancer, including colorectal, lung, breast, and kidney cancers. The global market for bevacizumab is being driven by several factors. The global prevalence of cancer is on the rise, primarily due to factors such as aging population, lifestyle changes, and environmental factors. This has led to a higher demand for effective cancer therapies like bevacizumab. Bevacizumab is considered a targeted therapy as it selectively inhibits the growth of blood vessels that feed tumors, thereby suppressing tumor growth and progression. The growing preference for targeted therapies among healthcare providers and patients is driving the market for bevacizumab. Bevacizumab has received regulatory approvals for the treatment of various types of cancers, including advanced colorectal, non-small cell lung, metastatic breast, and renal cell carcinoma. The expanding list of approved indications is contributing to the market growth. Improvements in healthcare infrastructure, particularly in emerging markets, have increased access to advanced cancer therapies like bevacizumab. This has led to a wider patient pool and increased market demand. Governments and private entities are investing heavily in healthcare, including cancer treatment. This increased healthcare spending is supporting the availability and affordability of bevacizumab, driving market growth.
This report aims to provide a comprehensive presentation of the global market for Bevacizumab, with both quantitative and qualitative analysis, to help readers develop business/growth strategies, assess the market competitive situation, analyze their position in the current marketplace, and make informed business decisions regarding Bevacizumab.
Report Scope
The Bevacizumab market size, estimations, and forecasts are provided in terms of sales volume (K Units) and revenue ($ millions), considering 2023 as the base year, with history and forecast data for the period from 2019 to 2030. This report segments the global Bevacizumab market comprehensively. Regional market sizes, concerning products by Type, by Application, and by players, are also provided.
For a more in-depth understanding of the market, the report provides profiles of the competitive landscape, key competitors, and their respective market ranks. The report also discusses technological trends and new product developments.
The report will help the Bevacizumab manufacturers, new entrants, and industry chain related companies in this market with information on the revenues, sales volume, and average price for the overall market and the sub-segments across the different segments, by company, by Type, by Application, and by regions.
Market Segmentation
By Company
Genentech
Amgen
Aark Pharmaceuticals
Beacon Pharmaceuticals Limited
Balaji Medical Services Private Limited
MVASI (bevacizumab)
Mylan
Segment by Type
Avastin (bevacizumab)
Mvasi (bevacizumab-awwb)
Segment by Application
Cancer
Eye Diease
Consumption by Region
North America
U.S.
Canada
Europe
Germany
France
U.K.
Italy
Russia
Asia-Pacific
China
Japan
South Korea
India
Australia
Taiwan
Indonesia
Thailand
Malaysia
Philippines
Vietnam
Latin America
Mexico
Brazil
Argentina
Middle East & Africa
Turkey
Saudi Arabia
U.A.E
Chapter Outline
Chapter 1: Introduces the report scope of the report, executive summary of different market segments (by region, by Type, by Application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter 2: Detailed analysis of Bevacizumab manufacturers competitive landscape, price, sales and revenue market share, latest development plan, merger, and acquisition information, etc.
Chapter 3: Sales, revenue of Bevacizumab in regional level and country level. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and market size of each country in the world.
Chapter 4: Provides the analysis of various market segments by Type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 5: Provides the analysis of various market segments by Application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 6: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.
Chapter 7: Analysis of industrial chain, including the upstream and downstream of the industry.
Chapter 8: Introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.
Chapter 9: The main points and conclusions of the report.
Bevacizumab, sold under the trade name Avastin, is a medication used to treat a number of types of cancers and a specific eye disease.
The global Bevacizumab market was valued at US$ 61 million in 2023 and is anticipated to reach US$ 82 million by 2030, witnessing a CAGR of 4.4% during the forecast period 2024-2030.
Bevacizumab is a monoclonal antibody used for the treatment of various types of cancer, including colorectal, lung, breast, and kidney cancers. The global market for bevacizumab is being driven by several factors. The global prevalence of cancer is on the rise, primarily due to factors such as aging population, lifestyle changes, and environmental factors. This has led to a higher demand for effective cancer therapies like bevacizumab. Bevacizumab is considered a targeted therapy as it selectively inhibits the growth of blood vessels that feed tumors, thereby suppressing tumor growth and progression. The growing preference for targeted therapies among healthcare providers and patients is driving the market for bevacizumab. Bevacizumab has received regulatory approvals for the treatment of various types of cancers, including advanced colorectal, non-small cell lung, metastatic breast, and renal cell carcinoma. The expanding list of approved indications is contributing to the market growth. Improvements in healthcare infrastructure, particularly in emerging markets, have increased access to advanced cancer therapies like bevacizumab. This has led to a wider patient pool and increased market demand. Governments and private entities are investing heavily in healthcare, including cancer treatment. This increased healthcare spending is supporting the availability and affordability of bevacizumab, driving market growth.
This report aims to provide a comprehensive presentation of the global market for Bevacizumab, with both quantitative and qualitative analysis, to help readers develop business/growth strategies, assess the market competitive situation, analyze their position in the current marketplace, and make informed business decisions regarding Bevacizumab.
Report Scope
The Bevacizumab market size, estimations, and forecasts are provided in terms of sales volume (K Units) and revenue ($ millions), considering 2023 as the base year, with history and forecast data for the period from 2019 to 2030. This report segments the global Bevacizumab market comprehensively. Regional market sizes, concerning products by Type, by Application, and by players, are also provided.
For a more in-depth understanding of the market, the report provides profiles of the competitive landscape, key competitors, and their respective market ranks. The report also discusses technological trends and new product developments.
The report will help the Bevacizumab manufacturers, new entrants, and industry chain related companies in this market with information on the revenues, sales volume, and average price for the overall market and the sub-segments across the different segments, by company, by Type, by Application, and by regions.
Market Segmentation
By Company
Genentech
Amgen
Aark Pharmaceuticals
Beacon Pharmaceuticals Limited
Balaji Medical Services Private Limited
MVASI (bevacizumab)
Mylan
Segment by Type
Avastin (bevacizumab)
Mvasi (bevacizumab-awwb)
Segment by Application
Cancer
Eye Diease
Consumption by Region
North America
U.S.
Canada
Europe
Germany
France
U.K.
Italy
Russia
Asia-Pacific
China
Japan
South Korea
India
Australia
Taiwan
Indonesia
Thailand
Malaysia
Philippines
Vietnam
Latin America
Mexico
Brazil
Argentina
Middle East & Africa
Turkey
Saudi Arabia
U.A.E
Chapter Outline
Chapter 1: Introduces the report scope of the report, executive summary of different market segments (by region, by Type, by Application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter 2: Detailed analysis of Bevacizumab manufacturers competitive landscape, price, sales and revenue market share, latest development plan, merger, and acquisition information, etc.
Chapter 3: Sales, revenue of Bevacizumab in regional level and country level. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and market size of each country in the world.
Chapter 4: Provides the analysis of various market segments by Type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 5: Provides the analysis of various market segments by Application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 6: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.
Chapter 7: Analysis of industrial chain, including the upstream and downstream of the industry.
Chapter 8: Introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.
Chapter 9: The main points and conclusions of the report.
Index1 Bevacizumab Market Overview
1.1 Product Overview and Scope of Bevacizumab
1.2 Bevacizumab Segment by Type
1.2.1 Global Bevacizumab Market Value Comparison by Type (2024-2030)
1.2.2 Avastin (bevacizumab)
1.2.3 Mvasi (bevacizumab-awwb)
1.3 Bevacizumab Segment by Application
1.3.1 Global Bevacizumab Market Value by Application: (2024-2030)
1.3.2 Cancer
1.3.3 Eye Diease
1.4 Global Bevacizumab Market Size Estimates and Forecasts
1.4.1 Global Bevacizumab Revenue 2019-2030
1.4.2 Global Bevacizumab Sales 2019-2030
1.4.3 Global Bevacizumab Market Average Price (2019-2030)
1.5 Assumptions and Limitations
2 Bevacizumab Market Competition by Manufacturers
2.1 Global Bevacizumab Sales Market Share by Manufacturers (2019-2024)
2.2 Global Bevacizumab Revenue Market Share by Manufacturers (2019-2024)
2.3 Global Bevacizumab Average Price by Manufacturers (2019-2024)
2.4 Global Bevacizumab Industry Ranking 2022 VS 2023 VS 2024
2.5 Global Key Manufacturers of Bevacizumab, Manufacturing Sites & Headquarters
2.6 Global Key Manufacturers of Bevacizumab, Product Type & Application
2.7 Bevacizumab Market Competitive Situation and Trends
2.7.1 Bevacizumab Market Concentration Rate
2.7.2 The Global Top 5 and Top 10 Largest Bevacizumab Players Market Share by Revenue
2.7.3 Global Bevacizumab Market Share by Company Type (Tier 1, Tier 2 and Tier 3)
2.8 Manufacturers Mergers & Acquisitions, Expansion Plans
3 Bevacizumab Retrospective Market Scenario by Region
3.1 Global Bevacizumab Market Size by Region: 2019 Versus 2023 Versus 2030
3.2 Global Bevacizumab Global Bevacizumab Sales by Region: 2019-2030
3.2.1 Global Bevacizumab Sales by Region: 2019-2024
3.2.2 Global Bevacizumab Sales by Region: 2025-2030
3.3 Global Bevacizumab Global Bevacizumab Revenue by Region: 2019-2030
3.3.1 Global Bevacizumab Revenue by Region: 2019-2024
3.3.2 Global Bevacizumab Revenue by Region: 2025-2030
3.4 North America Bevacizumab Market Facts & Figures by Country
3.4.1 North America Bevacizumab Market Size by Country: 2019 VS 2023 VS 2030
3.4.2 North America Bevacizumab Sales by Country (2019-2030)
3.4.3 North America Bevacizumab Revenue by Country (2019-2030)
3.4.4 U.S.
3.4.5 Canada
3.5 Europe Bevacizumab Market Facts & Figures by Country
3.5.1 Europe Bevacizumab Market Size by Country: 2019 VS 2023 VS 2030
3.5.2 Europe Bevacizumab Sales by Country (2019-2030)
3.5.3 Europe Bevacizumab Revenue by Country (2019-2030)
3.5.4 Germany
3.5.5 France
3.5.6 U.K.
3.5.7 Italy
3.5.8 Russia
3.6 Asia Pacific Bevacizumab Market Facts & Figures by Country
3.6.1 Asia Pacific Bevacizumab Market Size by Country: 2019 VS 2023 VS 2030
3.6.2 Asia Pacific Bevacizumab Sales by Country (2019-2030)
3.6.3 Asia Pacific Bevacizumab Revenue by Country (2019-2030)
3.6.4 China
3.6.5 Japan
3.6.6 South Korea
3.6.7 India
3.6.8 Australia
3.6.9 Taiwan
3.6.10 Indonesia
3.6.11 Thailand
3.6.12 Malaysia
3.6.13 Philippines
3.7 Latin America Bevacizumab Market Facts & Figures by Country
3.7.1 Latin America Bevacizumab Market Size by Country: 2019 VS 2023 VS 2030
3.7.2 Latin America Bevacizumab Sales by Country (2019-2030)
3.7.3 Latin America Bevacizumab Revenue by Country (2019-2030)
3.7.4 Mexico
3.7.5 Brazil
3.7.6 Argentina
3.8 Middle East and Africa Bevacizumab Market Facts & Figures by Country
3.8.1 Middle East and Africa Bevacizumab Market Size by Country: 2019 VS 2023 VS 2030
3.8.2 Middle East and Africa Bevacizumab Sales by Country (2019-2030)
3.8.3 Middle East and Africa Bevacizumab Revenue by Country (2019-2030)
3.8.4 Turkey
3.8.5 Saudi Arabia
3.8.6 U.A.E
4 Segment by Type
4.1 Global Bevacizumab Sales by Type (2019-2030)
4.1.1 Global Bevacizumab Sales by Type (2019-2024)
4.1.2 Global Bevacizumab Sales by Type (2025-2030)
4.1.3 Global Bevacizumab Sales Market Share by Type (2019-2030)
4.2 Global Bevacizumab Revenue by Type (2019-2030)
4.2.1 Global Bevacizumab Revenue by Type (2019-2024)
4.2.2 Global Bevacizumab Revenue by Type (2025-2030)
4.2.3 Global Bevacizumab Revenue Market Share by Type (2019-2030)
4.3 Global Bevacizumab Price by Type (2019-2030)
5 Segment by Application
5.1 Global Bevacizumab Sales by Application (2019-2030)
5.1.1 Global Bevacizumab Sales by Application (2019-2024)
5.1.2 Global Bevacizumab Sales by Application (2025-2030)
5.1.3 Global Bevacizumab Sales Market Share by Application (2019-2030)
5.2 Global Bevacizumab Revenue by Application (2019-2030)
5.2.1 Global Bevacizumab Revenue by Application (2019-2024)
5.2.2 Global Bevacizumab Revenue by Application (2025-2030)
5.2.3 Global Bevacizumab Revenue Market Share by Application (2019-2030)
5.3 Global Bevacizumab Price by Application (2019-2030)
6 Key Companies Profiled
6.1 Genentech
6.1.1 Genentech Corporation Information
6.1.2 Genentech Description and Business Overview
6.1.3 Genentech Bevacizumab Sales, Revenue and Gross Margin (2019-2024)
6.1.4 Genentech Bevacizumab Product Portfolio
6.1.5 Genentech Recent Developments/Updates
6.2 Amgen
6.2.1 Amgen Corporation Information
6.2.2 Amgen Description and Business Overview
6.2.3 Amgen Bevacizumab Sales, Revenue and Gross Margin (2019-2024)
6.2.4 Amgen Bevacizumab Product Portfolio
6.2.5 Amgen Recent Developments/Updates
6.3 Aark Pharmaceuticals
6.3.1 Aark Pharmaceuticals Corporation Information
6.3.2 Aark Pharmaceuticals Description and Business Overview
6.3.3 Aark Pharmaceuticals Bevacizumab Sales, Revenue and Gross Margin (2019-2024)
6.3.4 Aark Pharmaceuticals Bevacizumab Product Portfolio
6.3.5 Aark Pharmaceuticals Recent Developments/Updates
6.4 Beacon Pharmaceuticals Limited
6.4.1 Beacon Pharmaceuticals Limited Corporation Information
6.4.2 Beacon Pharmaceuticals Limited Description and Business Overview
6.4.3 Beacon Pharmaceuticals Limited Bevacizumab Sales, Revenue and Gross Margin (2019-2024)
6.4.4 Beacon Pharmaceuticals Limited Bevacizumab Product Portfolio
6.4.5 Beacon Pharmaceuticals Limited Recent Developments/Updates
6.5 Balaji Medical Services Private Limited
6.5.1 Balaji Medical Services Private Limited Corporation Information
6.5.2 Balaji Medical Services Private Limited Description and Business Overview
6.5.3 Balaji Medical Services Private Limited Bevacizumab Sales, Revenue and Gross Margin (2019-2024)
6.5.4 Balaji Medical Services Private Limited Bevacizumab Product Portfolio
6.5.5 Balaji Medical Services Private Limited Recent Developments/Updates
6.6 MVASI (bevacizumab)
6.6.1 MVASI (bevacizumab) Corporation Information
6.6.2 MVASI (bevacizumab) Description and Business Overview
6.6.3 MVASI (bevacizumab) Bevacizumab Sales, Revenue and Gross Margin (2019-2024)
6.6.4 MVASI (bevacizumab) Bevacizumab Product Portfolio
6.6.5 MVASI (bevacizumab) Recent Developments/Updates
6.7 Mylan
6.6.1 Mylan Corporation Information
6.6.2 Mylan Description and Business Overview
6.6.3 Mylan Bevacizumab Sales, Revenue and Gross Margin (2019-2024)
6.4.4 Mylan Bevacizumab Product Portfolio
6.7.5 Mylan Recent Developments/Updates
7 Industry Chain and Sales Channels Analysis
7.1 Bevacizumab Industry Chain Analysis
7.2 Bevacizumab Key Raw Materials
7.2.1 Key Raw Materials
7.2.2 Raw Materials Key Suppliers
7.3 Bevacizumab Production Mode & Process
7.4 Bevacizumab Sales and Marketing
7.4.1 Bevacizumab Sales Channels
7.4.2 Bevacizumab Distributors
7.5 Bevacizumab Customers
8 Bevacizumab Market Dynamics
8.1 Bevacizumab Industry Trends
8.2 Bevacizumab Market Drivers
8.3 Bevacizumab Market Challenges
8.4 Bevacizumab Market Restraints
9 Research Finding and Conclusion
10 Methodology and Data Source
10.1 Methodology/Research Approach
10.1.1 Research Programs/Design
10.1.2 Market Size Estimation
10.1.3 Market Breakdown and Data Triangulation
10.2 Data Source
10.2.1 Secondary Sources
10.2.2 Primary Sources
10.3 Author List
10.4 Disclaimer
List of TablesList of Tables
Table 1. Global Bevacizumab Market Value Comparison by Type (2024-2030) & (US$ Million)
Table 2. Global Bevacizumab Market Value Comparison by Application (2024-2030) & (US$ Million)
Table 3. Global Bevacizumab Market Competitive Situation by Manufacturers in 2023
Table 4. Global Bevacizumab Sales (K Units) of Key Manufacturers (2019-2024)
Table 5. Global Bevacizumab Sales Market Share by Manufacturers (2019-2024)
Table 6. Global Bevacizumab Revenue (US$ Million) by Manufacturers (2019-2024)
Table 7. Global Bevacizumab Revenue Share by Manufacturers (2019-2024)
Table 8. Global Market Bevacizumab Average Price (USD/Unit) of Key Manufacturers (2019-2024)
Table 9. Global Key Players of Bevacizumab, Industry Ranking, 2022 VS 2023 VS 2024
Table 10. Global Key Manufacturers of Bevacizumab, Manufacturing Sites & Headquarters
Table 11. Global Key Manufacturers of Bevacizumab, Product Type & Application
Table 12. Global Key Manufacturers of Bevacizumab, Date of Enter into This Industry
Table 13. Global Manufacturers Market Concentration Ratio (CR5 and HHI)
Table 14. Global Bevacizumab by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Bevacizumab as of 2023)
Table 15. Manufacturers Mergers & Acquisitions, Expansion Plans
Table 16. Global Bevacizumab Market Size by Region (US$ Million): 2019 VS 2023 VS 2030
Table 17. Global Bevacizumab Sales by Region (2019-2024) & (K Units)
Table 18. Global Bevacizumab Sales Market Share by Region (2019-2024)
Table 19. Global Bevacizumab Sales by Region (2025-2030) & (K Units)
Table 20. Global Bevacizumab Sales Market Share by Region (2025-2030)
Table 21. Global Bevacizumab Revenue by Region (2019-2024) & (US$ Million)
Table 22. Global Bevacizumab Revenue Market Share by Region (2019-2024)
Table 23. Global Bevacizumab Revenue by Region (2025-2030) & (US$ Million)
Table 24. Global Bevacizumab Revenue Market Share by Region (2025-2030)
Table 25. North America Bevacizumab Revenue by Country: 2019 VS 2023 VS 2030 (US$ Million)
Table 26. North America Bevacizumab Sales by Country (2019-2024) & (K Units)
Table 27. North America Bevacizumab Sales by Country (2025-2030) & (K Units)
Table 28. North America Bevacizumab Revenue by Country (2019-2024) & (US$ Million)
Table 29. North America Bevacizumab Revenue by Country (2025-2030) & (US$ Million)
Table 30. Europe Bevacizumab Revenue by Country: 2019 VS 2023 VS 2030 (US$ Million)
Table 31. Europe Bevacizumab Sales by Country (2019-2024) & (K Units)
Table 32. Europe Bevacizumab Sales by Country (2025-2030) & (K Units)
Table 33. Europe Bevacizumab Revenue by Country (2019-2024) & (US$ Million)
Table 34. Europe Bevacizumab Revenue by Country (2025-2030) & (US$ Million)
Table 35. Asia Pacific Bevacizumab Revenue by Region: 2019 VS 2023 VS 2030 (US$ Million)
Table 36. Asia Pacific Bevacizumab Sales by Region (2019-2024) & (K Units)
Table 37. Asia Pacific Bevacizumab Sales by Region (2025-2030) & (K Units)
Table 38. Asia Pacific Bevacizumab Revenue by Region (2019-2024) & (US$ Million)
Table 39. Asia Pacific Bevacizumab Revenue by Region (2025-2030) & (US$ Million)
Table 40. Latin America Bevacizumab Revenue by Country: 2019 VS 2023 VS 2030 (US$ Million)
Table 41. Latin America Bevacizumab Sales by Country (2019-2024) & (K Units)
Table 42. Latin America Bevacizumab Sales by Country (2025-2030) & (K Units)
Table 43. Latin America Bevacizumab Revenue by Country (2019-2024) & (US$ Million)
Table 44. Latin America Bevacizumab Revenue by Country (2025-2030) & (US$ Million)
Table 45. Middle East & Africa Bevacizumab Revenue by Country: 2019 VS 2023 VS 2030 (US$ Million)
Table 46. Middle East & Africa Bevacizumab Sales by Country (2019-2024) & (K Units)
Table 47. Middle East & Africa Bevacizumab Sales by Country (2025-2030) & (K Units)
Table 48. Middle East & Africa Bevacizumab Revenue by Country (2019-2024) & (US$ Million)
Table 49. Middle East & Africa Bevacizumab Revenue by Country (2025-2030) & (US$ Million)
Table 50. Global Bevacizumab Sales (K Units) by Type (2019-2024)
Table 51. Global Bevacizumab Sales (K Units) by Type (2025-2030)
Table 52. Global Bevacizumab Sales Market Share by Type (2019-2024)
Table 53. Global Bevacizumab Sales Market Share by Type (2025-2030)
Table 54. Global Bevacizumab Revenue (US$ Million) by Type (2019-2024)
Table 55. Global Bevacizumab Revenue (US$ Million) by Type (2025-2030)
Table 56. Global Bevacizumab Revenue Market Share by Type (2019-2024)
Table 57. Global Bevacizumab Revenue Market Share by Type (2025-2030)
Table 58. Global Bevacizumab Price (USD/Unit) by Type (2019-2024)
Table 59. Global Bevacizumab Price (USD/Unit) by Type (2025-2030)
Table 60. Global Bevacizumab Sales (K Units) by Application (2019-2024)
Table 61. Global Bevacizumab Sales (K Units) by Application (2025-2030)
Table 62. Global Bevacizumab Sales Market Share by Application (2019-2024)
Table 63. Global Bevacizumab Sales Market Share by Application (2025-2030)
Table 64. Global Bevacizumab Revenue (US$ Million) by Application (2019-2024)
Table 65. Global Bevacizumab Revenue (US$ Million) by Application (2025-2030)
Table 66. Global Bevacizumab Revenue Market Share by Application (2019-2024)
Table 67. Global Bevacizumab Revenue Market Share by Application (2025-2030)
Table 68. Global Bevacizumab Price (USD/Unit) by Application (2019-2024)
Table 69. Global Bevacizumab Price (USD/Unit) by Application (2025-2030)
Table 70. Genentech Corporation Information
Table 71. Genentech Description and Business Overview
Table 72. Genentech Bevacizumab Sales (K Units), Revenue (US$ Million), Price (USD/Unit) and Gross Margin (2019-2024)
Table 73. Genentech Bevacizumab Product
Table 74. Genentech Recent Developments/Updates
Table 75. Amgen Corporation Information
Table 76. Amgen Description and Business Overview
Table 77. Amgen Bevacizumab Sales (K Units), Revenue (US$ Million), Price (USD/Unit) and Gross Margin (2019-2024)
Table 78. Amgen Bevacizumab Product
Table 79. Amgen Recent Developments/Updates
Table 80. Aark Pharmaceuticals Corporation Information
Table 81. Aark Pharmaceuticals Description and Business Overview
Table 82. Aark Pharmaceuticals Bevacizumab Sales (K Units), Revenue (US$ Million), Price (USD/Unit) and Gross Margin (2019-2024)
Table 83. Aark Pharmaceuticals Bevacizumab Product
Table 84. Aark Pharmaceuticals Recent Developments/Updates
Table 85. Beacon Pharmaceuticals Limited Corporation Information
Table 86. Beacon Pharmaceuticals Limited Description and Business Overview
Table 87. Beacon Pharmaceuticals Limited Bevacizumab Sales (K Units), Revenue (US$ Million), Price (USD/Unit) and Gross Margin (2019-2024)
Table 88. Beacon Pharmaceuticals Limited Bevacizumab Product
Table 89. Beacon Pharmaceuticals Limited Recent Developments/Updates
Table 90. Balaji Medical Services Private Limited Corporation Information
Table 91. Balaji Medical Services Private Limited Description and Business Overview
Table 92. Balaji Medical Services Private Limited Bevacizumab Sales (K Units), Revenue (US$ Million), Price (USD/Unit) and Gross Margin (2019-2024)
Table 93. Balaji Medical Services Private Limited Bevacizumab Product
Table 94. Balaji Medical Services Private Limited Recent Developments/Updates
Table 95. MVASI (bevacizumab) Corporation Information
Table 96. MVASI (bevacizumab) Description and Business Overview
Table 97. MVASI (bevacizumab) Bevacizumab Sales (K Units), Revenue (US$ Million), Price (USD/Unit) and Gross Margin (2019-2024)
Table 98. MVASI (bevacizumab) Bevacizumab Product
Table 99. MVASI (bevacizumab) Recent Developments/Updates
Table 100. Mylan Corporation Information
Table 101. Mylan Description and Business Overview
Table 102. Mylan Bevacizumab Sales (K Units), Revenue (US$ Million), Price (USD/Unit) and Gross Margin (2019-2024)
Table 103. Mylan Bevacizumab Product
Table 104. Mylan Recent Developments/Updates
Table 105. Key Raw Materials Lists
Table 106. Raw Materials Key Suppliers Lists
Table 107. Bevacizumab Distributors List
Table 108. Bevacizumab Customers List
Table 109. Bevacizumab Market Trends
Table 110. Bevacizumab Market Drivers
Table 111. Bevacizumab Market Challenges
Table 112. Bevacizumab Market Restraints
Table 113. Research Programs/Design for This Report
Table 114. Key Data Information from Secondary Sources
Table 115. Key Data Information from Primary Sources
List of Figures
Figure 1. Product Picture of Bevacizumab
Figure 2. Global Bevacizumab Market Value Comparison by Type (2024-2030) & (US$ Million)
Figure 3. Global Bevacizumab Market Share by Type in 2023 & 2030
Figure 4. Avastin (bevacizumab) Product Picture
Figure 5. Mvasi (bevacizumab-awwb) Product Picture
Figure 6. Global Bevacizumab Market Value Comparison by Application (2024-2030) & (US$ Million)
Figure 7. Global Bevacizumab Market Share by Application in 2023 & 2030
Figure 8. Cancer
Figure 9. Eye Diease
Figure 10. Global Bevacizumab Revenue, (US$ Million), 2019 VS 2023 VS 2030
Figure 11. Global Bevacizumab Market Size (2019-2030) & (US$ Million)
Figure 12. Global Bevacizumab Sales (2019-2030) & (K Units)
Figure 13. Global Bevacizumab Average Price (USD/Unit) & (2019-2030)
Figure 14. Bevacizumab Report Years Considered
Figure 15. Bevacizumab Sales Share by Manufacturers in 2023
Figure 16. Global Bevacizumab Revenue Share by Manufacturers in 2023
Figure 17. The Global 5 and 10 Largest Bevacizumab Players: Market Share by Revenue in 2023
Figure 18. Bevacizumab Market Share by Company Type (Tier 1, Tier 2 and Tier 3): 2019 VS 2023
Figure 19. Global Bevacizumab Market Size by Region (US$ Million): 2019 VS 2023 VS 2030
Figure 20. North America Bevacizumab Sales Market Share by Country (2019-2030)
Figure 21. North America Bevacizumab Revenue Market Share by Country (2019-2030)
Figure 22. U.S. Bevacizumab Revenue Growth Rate (2019-2030) & (US$ Million)
Figure 23. Canada Bevacizumab Revenue Growth Rate (2019-2030) & (US$ Million)
Figure 24. Europe Bevacizumab Sales Market Share by Country (2019-2030)
Figure 25. Europe Bevacizumab Revenue Market Share by Country (2019-2030)
Figure 26. Germany Bevacizumab Revenue Growth Rate (2019-2030) & (US$ Million)
Figure 27. France Bevacizumab Revenue Growth Rate (2019-2030) & (US$ Million)
Figure 28. U.K. Bevacizumab Revenue Growth Rate (2019-2030) & (US$ Million)
Figure 29. Italy Bevacizumab Revenue Growth Rate (2019-2030) & (US$ Million)
Figure 30. Russia Bevacizumab Revenue Growth Rate (2019-2030) & (US$ Million)
Figure 31. Asia Pacific Bevacizumab Sales Market Share by Region (2019-2030)
Figure 32. Asia Pacific Bevacizumab Revenue Market Share by Region (2019-2030)
Figure 33. China Bevacizumab Revenue Growth Rate (2019-2030) & (US$ Million)
Figure 34. Japan Bevacizumab Revenue Growth Rate (2019-2030) & (US$ Million)
Figure 35. South Korea Bevacizumab Revenue Growth Rate (2019-2030) & (US$ Million)
Figure 36. India Bevacizumab Revenue Growth Rate (2019-2030) & (US$ Million)
Figure 37. Australia Bevacizumab Revenue Growth Rate (2019-2030) & (US$ Million)
Figure 38. Taiwan Bevacizumab Revenue Growth Rate (2019-2030) & (US$ Million)
Figure 39. Indonesia Bevacizumab Revenue Growth Rate (2019-2030) & (US$ Million)
Figure 40. Thailand Bevacizumab Revenue Growth Rate (2019-2030) & (US$ Million)
Figure 41. Malaysia Bevacizumab Revenue Growth Rate (2019-2030) & (US$ Million)
Figure 42. Philippines Bevacizumab Revenue Growth Rate (2019-2030) & (US$ Million)
Figure 43. Latin America Bevacizumab Sales Market Share by Country (2019-2030)
Figure 44. Latin America Bevacizumab Revenue Market Share by Country (2019-2030)
Figure 45. Mexico Bevacizumab Revenue Growth Rate (2019-2030) & (US$ Million)
Figure 46. Brazil Bevacizumab Revenue Growth Rate (2019-2030) & (US$ Million)
Figure 47. Argentina Bevacizumab Revenue Growth Rate (2019-2030) & (US$ Million)
Figure 48. Middle East & Africa Bevacizumab Sales Market Share by Country (2019-2030)
Figure 49. Middle East & Africa Bevacizumab Revenue Market Share by Country (2019-2030)
Figure 50. Turkey Bevacizumab Revenue Growth Rate (2019-2030) & (US$ Million)
Figure 51. Saudi Arabia Bevacizumab Revenue Growth Rate (2019-2030) & (US$ Million)
Figure 52. U.A.E Bevacizumab Revenue Growth Rate (2019-2030) & (US$ Million)
Figure 53. Global Sales Market Share of Bevacizumab by Type (2019-2030)
Figure 54. Global Revenue Market Share of Bevacizumab by Type (2019-2030)
Figure 55. Global Bevacizumab Price (USD/Unit) by Type (2019-2030)
Figure 56. Global Sales Market Share of Bevacizumab by Application (2019-2030)
Figure 57. Global Revenue Market Share of Bevacizumab by Application (2019-2030)
Figure 58. Global Bevacizumab Price (USD/Unit) by Application (2019-2030)
Figure 59. Bevacizumab Value Chain
Figure 60. Bevacizumab Production Process
Figure 61. Channels of Distribution (Direct Vs Distribution)
Figure 62. Distributors Profiles
Figure 63. Bottom-up and Top-down Approaches for This Report
Figure 64. Data Triangulation
Figure 65. Key Executives Interviewed
Published By : QY Research
Why ‘The Market Reports’
In Business:
Pre Sales Support:
Post Sales Support:
Turn Around Time:
Clients Served:
Clients Assisted:
Client Types:
Payment:
- Accept global payments [Credit Card / PayPal / Wire Transfer]
- Accept local payments in South Korea, Germany, China and India [Can pay in local currency]
Latest Life Science Market Reports
Payments Accepted From
Connect with us at
Complete Secure Website
